L 870810
| Code | Size | Price |
|---|
| TAR-T24366-5mg | 5mg | £930.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T24366-50mg | 50mg | £1,821.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T24366-100mg | 100mg | £2,319.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
L 870810 is a small-molecule inhibitor of HIV-1 integrase with potent antiviral activity in cell culture and good pharmacokinetic properties.
CAS:
410544-95-5
Formula:
C20H19FN4O4S
Molecular Weight:
430.45
Purity:
0.98
SMILES:
Oc1c(nc(N2CCCCS2(=O)=O)c2cccnc12)C(=O)NCc1ccc(F)cc1
References
1. Markopoulos C, Vertzoni M, Symillides M, Kesisoglou F, Reppas C. Two-Stage Single-Compartment Models to Evaluate Dissolution in the Lower Intestine. J Pharm Sci. 2015 Sep;104(9):2986-97. doi: 10.1002/jps.24485. Epub 2015 May 18. PubMed PMID: 25989323.
2. Petrakis O, Vertzoni M, Angelou A, Kesisoglou F, Bentz K, Goumas K, Reppas C. Identification of key factors affecting the oral absorption of salts of lipophilic weak acids: a case example. J Pharm Pharmacol. 2015 Jan;67(1):56-67. doi: 10.1111/jphp.12320. Epub 2014 Sep 23. PubMed PMID: 25252222.
3. Zeng LF, Wang Y, Kazemi R, Xu S, Xu ZL, Sanchez TW, Yang LM, Debnath B, Odde S, Xie H, Zheng YT, Ding J, Neamati N, Long YQ. Repositioning HIV-1 integrase inhibitors for cancer therapeutics: 1,6-naphthyridine-7-carboxamide as a promising scaffold with drug-like properties. J Med Chem. 2012 Nov 26;55(22):9492-509. doi: 10.1021/jm300667v. Epub 2012 Nov 7. PubMed PMID: 23098137.
4. Low A, Prada N, Topper M, Vaida F, Castor D, Mohri H, Hazuda D, Muesing M, Markowitz M. Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors. Antimicrob Agents Chemother. 2009 Oct;53(10):4275-82. doi: 10.1128/AAC.00397-09. Epub 2009 Aug 3. PubMed PMID: 19651917; PubMed Central PMCID: PMC2764199.